salt forms of semaglutide FDA moves to remove GLP-1

Whether that balance holds across long-term use in diverse patients is exactly what the phase 3 program is designed to answer

GIP receptor agonism appears to amplify weight loss beyond what GLP-1 alone achieves, which is part of why dual agonists like tirzepatide outperform semaglutide in head-to-head comparisons

The single biggest factor affecting results is consistency daily evening application produces dramatically better outcomes than irregular use

They added that the effectiveness of a once-weekly dose of semaglutide to treat type 2 diabetes has been demonstrated in randomised controlled trials, but long-term data has been lacking